EASD 2025 - Simultaneous finerenone and empagliflozin was a safe therapy option in patients with diabetes and chronic kidney disease (CKD).

Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) joins us to discuss safety and efficacy findings from a double-blind, randomised, prespecified subanalysis of CONFIDENCE (NCT05254002), investigating simultaneous finerenone and empagliflozin therapy by baseline glucagon-like peptide-1 receptor agonist use in diabetes and CKD patients. The study also aimed to assess if the combination therapy would cause a greater reduction in albuminuria at day 180 than finerenone alone or empagliflozin alone.

Findings showed that the dual therapy was more safe and efficacious than the monotherapies, reducing albuminuria by 52% at day 180.

Interview Questions:
1. What is the reasoning behind the study?
2. What was the study design and patient population?
3. What were the key findings?
4. What are the take-home messages for practice?
5. What further research is needed in this area?

Recorded virtually from Indianapolis, 2025.

Editors: Jordan Rance, Yazmin Sadik.
Videographers: David Ben-Harosh
Support: This is an independent interview produced by Radcliffe CVRM.